BridgeBio Pharma (BBIO) Finished Goods (2025 - 2026)
BridgeBio Pharma (BBIO) posted Finished Goods of $8.0 million for Q1 2026, up 23.48% sequentially from $6.5 million in Q4 2025, and up 204.89% YoY from $2.6 million in Q1 2025.
Powered by 
Analysis
BridgeBio Pharma (BBIO) Finished Goods (2025 - 2026) Analysis & Trends
BridgeBio Pharma has reported Finished Goods for 2 years, with the latest figure at $8.0 million in Q1 2026.
- Quarterly Finished Goods rose 204.89% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 204.89% YoY) and the FY2025 annual result came in at $6.5 million, changed N/A from the prior year.
- Finished Goods grew to $8.0 million in Q1 2026 per BBIO's latest filing, from $6.5 million in the prior quarter.
- Over five years, Finished Goods peaked at $8.0 million in Q1 2026 and troughed at $2.6 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | BridgeBio Pharma | 14.65 Bn | 13.93 Bn | 228.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.12 Mn |
| Mar 31, 2026 | 8.04 Mn |
| Dec 31, 2025 | 6.51 Mn |
| Sep 30, 2025 | 4.97 Mn |
| Jun 30, 2025 | 5.75 Mn |
| Mar 31, 2025 | 2.64 Mn |